Detection of Epidermal Growth Factor Receptor Mutations in Formalin Fixed Paraffin Embedded Biopsies in Malaysian Non-small Cell Lung Cancer Patients

Overview

Journal J Biomed Sci

Publisher Biomed Central

Specialty Biology

Date 2013 Apr 18

PMID 23590575

Citations 5

Authors

Tiffany Ng Shi Yeen

Rajadurai Pathmanathan

Mohd Sidik Shiran

Fattah Azman Ahmad Zaid

Yoke Kqueen Cheah

Affiliations

Soon will be listed here.

Abstract

Background: Somatic mutations of the epidermal growth factor receptor (EGFR) are reportedly associated with various responses in non-small cell lung cancer (NSCLC) patients receiving the anti-EGFR agents. Detection of the mutation therefore plays an important role in therapeutic decision making. The aim of this study was to detect EGFR mutations in formalin fixed paraffin embedded (FFPE) samples using both Scorpion ARMS and high resolution melt (HRM) assay, and to compare the sensitivity of these methods.

Results: All of the mutations were found in adenocarcinoma, except one that was in squamous cell carcinoma. The mutation rate was 45.7% (221/484). Complex mutations were also observed, wherein 8 tumours carried 2 mutations and 1 tumour carried 3 mutations.

Conclusions: Both methods detected EGFR mutations in FFPE samples. HRM assays gave more EGFR positive results compared to Scorpion ARMS.

Citing Articles

Outcomes of Patients with Mutant Advanced NSCLC in a Developing Country in Southeast Asia.

How S, Liam C, Abidin M, Hasbullah H, Tho L, Ho G Cancer Manag Res. 2022; 14:1995-2005.

PMID: 35733510 PMC: 9208817. DOI: 10.2147/CMAR.S364713.

Uncommon Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.

Attili I, Passaro A, Pisapia P, Malapelle U, de Marinis F Curr Oncol. 2022; 29(1):255-266.

PMID: 35049698 PMC: 8774526. DOI: 10.3390/curroncol29010024.

EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

Midha A, Dearden S, McCormack R Am J Cancer Res. 2015; 5(9):2892-911.

PMID: 26609494 PMC: 4633915.

Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction.

Xu Q, Zhu Y, Bai Y, Wei X, Zheng X, Mao M Onco Targets Ther. 2015; 8:1533-41.

PMID: 26124670 PMC: 4482376. DOI: 10.2147/OTT.S84938.

Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing.

Lin J, Gu Y, Du R, Deng M, Lu Y, Ding Y Int J Clin Exp Pathol. 2015; 7(12):8813-22.

PMID: 25674250 PMC: 4313957.

References

John T, Liu G, Tsao M . Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene. 2009; 28 Suppl 1:S14-23. DOI: 10.1038/onc.2009.197. View

Krypuy M, Newnham G, Thomas D, Conron M, Dobrovic A . High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006; 6:295. PMC: 1769510. DOI: 10.1186/1471-2407-6-295. View

He M, Capelletti M, Nafa K, Yun C, Arcila M, Miller V . EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res. 2011; 18(6):1790-7. PMC: 3306520. DOI: 10.1158/1078-0432.CCR-11-2361. View

Su Z . Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now?. Thorac Cancer. 2011; 2(1):1-6. DOI: 10.1111/j.1759-7714.2010.00035.x. View

Mukohara T, Engelman J, Hanna N, Yeap B, Kobayashi S, Lindeman N . Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005; 97(16):1185-94. DOI: 10.1093/jnci/dji238. View

Do H, Krypuy M, Mitchell P, Fox S, Dobrovic A . High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 2008; 8:142. PMC: 2408599. DOI: 10.1186/1471-2407-8-142. View

Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S . Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005; 23(11):2513-20. DOI: 10.1200/JCO.2005.00.992. View

Norambuena P, Copeland J, Krenkova P, Stambergova A, Macek Jr M . Diagnostic method validation: High resolution melting (HRM) of small amplicons genotyping for the most common variants in the MTHFR gene. Clin Biochem. 2009; 42(12):1308-16. DOI: 10.1016/j.clinbiochem.2009.04.015. View

Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S . Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest. 2007; 131(6):1628-34. DOI: 10.1378/chest.06-1673. View

10.

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

11.

Salto-Tellez M, Tsao M, Shih J, Thongprasert S, Lu S, Chang G . Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol. 2011; 6(10):1663-9. DOI: 10.1097/JTO.0b013e318227816a. View

12.

Wu S, Chang Y, Hsu Y, Wu J, Yang C, Yu C . Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist. 2008; 13(12):1276-84. DOI: 10.1634/theoncologist.2008-0093. View

13.

Landis J, Koch G . The measurement of observer agreement for categorical data. Biometrics. 1977; 33(1):159-74. View

14.

Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B . Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res. 2006; 12(13):3915-21. DOI: 10.1158/1078-0432.CCR-05-2324. View

15.

Marchetti A, Del Grammastro M, Filice G, Felicioni L, Rossi G, Graziano P . Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS One. 2012; 7(7):e42164. PMC: 3407088. DOI: 10.1371/journal.pone.0042164. View

16.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

17.

Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U . Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005; 23(28):6829-37. DOI: 10.1200/JCO.2005.01.0793. View

18.

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View

19.

Stella G, Luisetti M, Inghilleri S, Cemmi F, Scabini R, Zorzetto M . Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. Respir Med. 2011; 106(2):173-83. DOI: 10.1016/j.rmed.2011.10.015. View

20.

Tam I, Leung E, Tin V, Chua D, Sihoe A, Cheng L . Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther. 2009; 8(8):2142-51. DOI: 10.1158/1535-7163.MCT-08-1219. View